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the models hip fracture was a specific outcome, 94% contained vertebral fractures,
and 77% containedwrist/forearm fractures. Elevenmodels incorporate at least one
extraskeletal effect on cost and survival (including breast cancer, coronary heart
disease, venous thromboembolism, stroke, and colorectal cancer). Thirty-two (32)
of the 48 publications (67%) assume 100% compliance or do not directly mention/
model compliance. The majority of the models take the approach that there was
discontinuation and non-compliance in the clinical trials, and that the treatment
efficacy rates sourced from the clinical trials are underestimated due to the use of
an intention-to-treat paradigm. CONCLUSIONS: The current state of osteoporosis
modeling favors a non-cohort Markov approach, with individualized, i.e., micro-
simulation methodology being increasingly utilized as extraskeletal effects are
incorporated. Treatment compliance and extraskeletal effects are extremely im-
portant in modeling real-world scenarios, yet they are not incorporated into the
majority of the published models. Modeled treatment effectiveness should be
properly imputed to account for the intention-to-treat impact of RCT-reported
values as well as the reduced benefits of treatment noncompliance.
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OBJECTIVES: Because of its prevalent condition and its association with hip frac-
tures in the elderly population, Osteoporosis has become a major concern for
health authorities in recent years. The objective of this study is to evaluate the
most cost-effective alternative for preventing hip fractures in osteoporosis patients
in Mexico. METHODS: A cost-effectiveness analysis was performed within an insti-
tutional setting (Mexican Institute of Social Security, IMSS). Patients were categorized
into 2 groups by age: group A was comprised with patients ages 60 to 79 years, and
groupBwascomprisedwithpatientsaged80years.Thestandardof carecomparator
usedwasall biphosphonates available in theNational Formulary: risedronate, original
alendronate, generic alendronate, and ibandronate. Resource use data was obtained
frompublished studies; total direct costs of osteoporosis and hip fractures were used.
The source of the unit costs was the institution, current for 2006. All costs are ex-
pressed in local currency (Mexican Pesos, MXP). The time horizon was 10 years; a
discount rate of 3%wasused. Effectiveness datawas obtained frompublished studies;
themeasureusedwaship fractures prevented. Aprobabilistic sensitivity analysiswas
obtained through a Monte Carlo simulation with 100,000 iterations in the weakest
parameters. RESULTS: In both groups, zoledronic acid was the most cost-effective
treatment. In group A, the C/E ratio was $221.43 MXP, as compared with $270.77 for
generic alendronate, $332.50 for ibandronate, $340.24 for risedronate and $353.32
for original ibandronate. Likewise, in group B the C/E ratio for zoledronic acid was
$574.50, as compared to $799.77 for generic alendronate, $941.52 for ibandronate,
$961.38 for risedronate, and $993.89 for original alendronate. The sensitivity anal-
ysis confirmed the robustness of the model. CONCLUSIONS: From an institutional
perspective, zoledronic acid is themost cost-effective alternative for the prevention of
hip fractures in patients with osteoporosis in Mexico.
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OBJECTIVES: High costs of rheumatoid arthritis (RA) and osteoarthritis (OA) due
not only to high morbidity, disability and mortality levels, but also basis medica-
tions and treatment of adverse events which are very expensive. METHODS: We
analyzed the efficacy and safety data from randomized clinical trials and system-
atic reviews of symptomatic treatment OA and RA patients with meloxicam and
diclofenac. We were searching data on: www.cochrane.org, www.pubmed.gov,
www.clinicaltrials.gov. Amodel “decision tree”was built based on two information
sources: 1) literature review; 2) cost databases. We calculate the average direct
costs of one serious cardiovascular thromboembolic adverse event and one serious
gastrointestinal adverse event in Ukraine. We determined the CER based on costs
from our “decision tree”model and data from the IMPROVE study. RESULTS:Direct
costs of one serious cardiovascular and gastrointestinal adverse event were
USD$590.29 andUSD$613.81 (1 USD$ 7.95UAHon 10.01.2011), respectively. Direct
costs of 60 days symptomatic treatment of 100 RA or OA patients with meloxicam
7.5 mg daily and diclofenac 100 mg daily were USD$2057.99 and USD$4975.22,
respectively. CERmeloxicamwas calculated 30.72 and CER diclofenac - 117.34. The
one-way sensitivity analysis performedwith themost relevant varables confirmed
this tendency. CONCLUSIONS: Results show that Meloxicam 7.5 daily is more eco-
nomical effective versus diclofenac 100 mg daily for symptomatic treatment of RA
and OA patients taking into account probability of serious cardiovascular trombo-
embolic and gastrointestinal adverse events.
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OBJECTIVES: To assess the cost-effectiveness of limited fasciectomy (LF), percuta-
neous needle fasciotomy (PNF), and collagenase clostridiumhistolyticum (CCH) for
the treatment of Dupuytren’s contracture.METHODS: AMarkov model was devel-
oped to simulate Dupuytren’s contracture progression and estimate clinical/eco-
nomic implications of LF, PNF, and CCH treatments from a US healthcare payer
perspective. Transition probabilities were assumed to follow a beta distribution
and were estimated based on results from randomized, clinical trials. Health state
utilities and direct costs of therapies were assumed to follow a gamma distribution
and obtained from published sources. Half-cycle correction was used with a 1-year
cycle length over a 10-year time horizon. One-way sensitivity analyses were per-
formed on relevant variables to test the robustness of the model. Probabilistic
sensitivity analysis was performed using 10,000 trial simulations for all variables
and results were presented as acceptability curves. Themodel used a discount rate
of 3% per annum and reported in 2010 $US dollars. Primary outcomes evaluated
incremental cost-effectiveness ratios. RESULTS: Of the 3 treatment decisions, LF
was the dominant strategy. PNF and CCH were estimated to cost an additional
$247 and $1844 compared to LF, respectively. An expected difference of0.1 and
0.04 quality-adjusted life years (QALYs) were projected for PNF and CCH rela-
tive to LF, respectively. In the one-way sensitivity analysis, the model was sen-
sitive to direct cost of LF with a break-even point of $2000 compared to PNF. The
acceptability curve showed that LF had a higher probability of being cost-effec-
tive compared to other treatment modalities across a WTP threshold of $0 to
$500,000. CONCLUSIONS:Across aWTP threshold between $0 and $500,000, LFwas
themost cost-effective therapy for the treatment of Dupuytren’s contracture com-
pared to PNF and CCH. However, the cost of surgery was sensitive in our model
which may vary from site to site.
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OBJECTIVES: To estimate the cost-effectiveness of denosumab vs. the most com-
monly used therapy (alendronatecolecalciferol) in treatment of post-menopausal
osteoporosis (PMO) in Portugal. METHODS: A Markov cost-utility life-cycle model
with six month cycle length was used. The analysis was undertaken from a Na-
tional Health Service (NHS) perspective. Efficacy data for denosumab was taken
from the FREEDOM randomized double-blind clinical trial and for the comparator
from a meta-analysis conducted by NICE. Epidemiological data were derived from
Portuguese sources and complemented with Swedish data whenever the former
were unavailable. Resource use data were collected through a modified Delphi
panel of Portuguese experts (including rheumatologists, GPs and orthopedic sur-
geons). Resources were valued using various national sources on unit costs. EQ-5D
decrements per fracture were based on the international literature. Expected per-
sistence differences between treatments were also considered. Deterministic sen-
sitivity analysis was conducted on key variables (including costs, utilities, impact
of fractures on mortality, non-inclusion of sub-optimal persistence, comparator’s
price, age and T-score for treatment initiation). Probabilistic sensitivity analysis
was performed on the model’s treatment effects, fracture costs, EQ-5D fracture
decrements and persistence rate differences. RESULTS: Considering an annual
NHS cost of €382.20 for denosumab, the estimated ICER was €14,487 per QALY
gained. The model predicts that, relative to the comparator, denosumab would
prevent 12 hip, 22 vertebral, 2 wrist and 1 other osteoporotic fractures, per 1000
patients, over a 10 year period. Deterministic sensitivity analysis identified the
absence of a persistence effect and the use of generic alendronate price as themost
sensitive parameters (22,906, 20,817 €/QALY, respectively). The probability of cost-
effectiveness ranged between 91% and 64% (willingness to pay set at 50,000 and
20,000 €/QALY, respectively). CONCLUSIONS: Results from the model suggest that,
compared to the most commonly used strategy (alendronatecolecalciferol), de-
nosumab is a cost-effective therapy in the treatment of PMO in Portugal.
PMS31
TITLE: THE RELATIVE COST-EFFECTIVENESS OF THE MOST COMMON
NON-SURGICAL TREATMENTS FOR NECK PAIN.
van der Velde G1, Hincapié C2, Schieir O2, Coté P3, Hogg-Johnson S4, Paulden M5,
Krahn M1
1Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON,
Canada, 2University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada,
3Toronto Western Research Institute, Toronto, ON, Canada, 4Institute for Work & Health,
Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada
OBJECTIVES: A major challenge facing policy makers is the lack of economic evi-
dence to guide their decisions about allocating health services for neck pain. Our
objective was to evaluate the cost-effectiveness of the most commonly used neck
pain treatments in Canada and the United States. METHODS: We conducted a
cost-utility analysis with a decision-analytic model of 5 treatments for neck pain
(exercise, cyclooxegenase-2 selective inhibitors, manipulation, mobilization, and
nonsteroidal anti-inflammatory drugs [NSAIDs]) using a lifetime time horizon and
adopting a health care system perspective. Model inputs included: estimates of the
course of neck pain; background risk of adverse events in the general population;
treatment effectiveness and risk of cerebrovascular, cardiovascular, and gastroin-
testinal adverse events; quality-of-life weights elicited from neck pain patients
using the standard gamble; and direct and out-of-pocket costs. Costs were ex-
pressed in 2008 Canadian prices. The impact of beneficial and harmful treatment
effects on health were expressed in quality-adjusted life years (QALYs). Cost-effec-
tiveness was estimated with the incremental cost-effectiveness ratio (ICER). The
probability that a given treatment was cost-effective was determined using a will-
ingness-to-pay (WTP) threshold of $50,000 per QALY. RESULTS: Under a conven-
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